LHLitang Huang

Litang Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Litang Huang has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Anqi Zhang

    Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200000, China

    1 shared publication
  • Chenhui Zhao

    Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200000, China

    1 shared publication
  • Hongxia Cheng

    Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200000, China

    1 shared publication
  • Lu Meng

    Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200000, China

    1 shared publication
  • Peng Li

    Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200000, China

    1 shared publication
  • Qing Shao

    Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200000, China

    1 shared publication

Latest Publications

  • Open Access

    Mechanisms Underlying Radioresistance and Reversal Strategies in Non-Small Cell Lung Cancer

    by Chenhui Zhao, Shilan Luo, Qing Shao, Peng Li, Litang Huang, Lu Meng, Hongxia Cheng, Anqi Zhang, Xiaomei Gong

    Radiotherapy (RT) continues to be a fundamental component in the management of non-small cell lung cancer (NSCLC). Nevertheless, some NSCLC patients do not attain optimal therapeutic outcomes due to the emergence of radioresistance. Improving the effectiveness of RT in NSCLC necessitates a thorough comprehension of the mechanisms that lead to radioresistance. This review delineates various potential mechanisms of radioresistance in NSCLC, encompassing augmented DNA damage repair, cell cycle dysregulation, cancer stem cells (CSCs), epithelial–mesenchymal transition (EMT), tumor hypoxia, an immunosuppressive tumor microenvironment (TME), dysregulation of cell death pathways, metabolic reprogramming, exosome-mediated signaling, genetic mutations, aberrant activation of signaling pathways, and epigenetic modifications. In addition, this study explores various novel strategies aimed at enhancing the radiosensitivity of NSCLC and provides a concise overview of potential biomarkers predictive of RT response, which may contribute to the development of innovative combination therapies to address radioresistance and improve patient outcomes.